Evaluation of rituximab therapy in real clinical practice (according to the OREL registry of patients with rheumatoid arthritis
Objective: to analyze therapy with rituximab (RTM) in real clinical practice according to the data available in OREL registry of patients with active rheumatoid arthritis (RA).Subjects and methods. The analysis included 349 patients. All the patients received RTM: 340 – the original drug (MabThera®)...
Saved in:
| Main Authors: | A. S. Avdeeva, A. M. Satybaldyev, N. V. Demidova, N. Yu. Nikishina, E. V. Gerasimova, N. V. Muravyeva, G. I. Gridneva, O. A. Rumyantseva, K. A. Kasumova, A. V. Alekseeva, N. V. Chichasova, D. A. Kusevich, V. V. Rybakova, E. A. Koshkarova, A. M. Lila, E. L. Nasonov |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2019-07-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/2725 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparative clinical characteristics of untreated early rheumatoid arthritis in patients with early and late onset according to the All-Russian Register of Patients with Arthritis “OREL”
by: A. M. Satybaldyev, et al.
Published: (2022-03-01) -
The impact of T2T therapy on the treatment of the patients with the early rheumatoid arthritis (data from OREL registry)
by: V. V. Rybakova, et al.
Published: (2021-07-01) -
ANALYSIS OF THE RESULTS OF TOFACITINIB THERAPY IN REAL CLINICAL PRACTICE ACCORDING TO THE ALL-RUSSIAN ARTHRITIS REGISTRY (OREL)
by: A. S. Avdeeva, et al.
Published: (2020-06-01) -
Clinical efficacy of the rituximab biosimilar Acellbia® 600 mg in patients with active rheumatoid arthritis in clinical practice
by: D. A. Kusevich, et al.
Published: (2019-01-01) -
IMMUNOLOGICAL EFFECTS OF A RITUXIMAB BIOSIMILAR (ACELBIA, BIOCAD) IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: A. S. Avdeeva, et al.
Published: (2018-11-01)